Please login to the form below

Not currently logged in
Email:
Password:

Merck files all-oral hepatitis C therapy in US

Seeking approval for grazoprevir and elbasvir, which already has FDA breakthrough status

Merck and Co - US headquartersMerck & Co has submitted its single-tablet combination therapy for hepatitis C virus (HCV) to the US FDA as it tries to catch up with the leading players in the all-oral therapy sector.

Merck - known as MSD outside the US - is seeking marketing approval for a once-daily fixed-dose combination of its NS3/4A protease inhibitor grazoprevir and elbasvir, an NS5A replication complex inhibitor, which has been awarded breakthrough status by the FDA.

If approved, the one-tablet, once-daily formulation will be a direct competitor to Gilead Science's Harvoni (sofosbuvir/ledipasvir), which is growing at a phenomenal rate since its launch towards the end of last year with first-quarter sales topping $3.5bn.

Merck has filed grazoprevir/elbasvir initially for the treatment of adult patients with chronic infections with HCV genotypes 1, 4 or 6, and says it will submit additional license applications in the EU and other markets by the end of the year.

While Merck is playing catch-up in the market with Harvoni and other rivals such as AbbVie's Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) - which achieved first-quarter sales of $231m - analysts have suggested its combination could eventually achieve sales in the region of $2bn a year.

A key factor in those predictions rests in the combination's benign profile in patients with HCV and concomitant kidney disease - in fact, the FDA's breakthrough designation was awarded specifically for the drug's use in patients with end stage renal disease who need haemodialysis as well as for those with genotype 4 HCV.

An earlier, more general breakthrough status in HCV was rescinded by the FDA after other all-oral HCV regimens reached the market.

In addition to kidney disease, Merck is also exploring the use of its drug in other hard-to-treat HCV setting - including co-infection with HIV, inherited blood disorders, liver cirrhosis and in patients receiving opiate substitution therapy to tackle addiction - that could help differentiate it from its rivals.

Meanwhile, Merck is also developing an HCV polymerase inhibitor - called MK-3682 - that it is testing alongside grazoprevir/elbasvir and other dual HCV therapies and is due to start phase III later this year.

Article by
Phil Taylor

29th May 2015

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
11 London

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....